Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe Eosinophilic Asthma

ClinicalTrials.gov ID: NCT01312961

Public ClinicalTrials.gov record NCT01312961. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 6:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy, Safety, and Tolerability of SAR231893/REGN668 Administered Subcutaneously Once Weekly for 12 Weeks in Patients With Persistent Moderate to Severe Eosinophilic Asthma Who Are Partially Controlled/Uncontrolled by Inhaled Corticosteroid Plus Long-acting beta2 Agonist Therapy

Study identification

NCT ID
NCT01312961
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Sanofi
Industry
Enrollment
104 participants

Conditions and interventions

Conditions

Interventions

  • Dupilumab Drug
  • Placebo (for Dupilumab) Drug
  • Fluticasone/Salmeterol combination therapy Drug
  • Fluticasone monotherapy Drug
  • Albuterol Drug
  • Levalbuterol Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 28, 2011
Primary completion
Sep 30, 2012
Completion
Sep 30, 2012
Last update posted
Jun 7, 2017

2011 – 2012

United States locations

U.S. sites
50
U.S. states
26
U.S. cities
45
Facility City State ZIP Site status
Investigational Site Number 840047 Anaheim California 92804
Investigational Site Number 840046 Long Beach California 90806
Investigational Site Number 840032 Los Angeles California 90025
Investigational Site Number 840036 Los Angeles California 90048
Investigational Site Number 840005 Mission Viejo California 92691
Investigational Site Number 840007 Orange California 92868
Investigational Site Number 840048 Riverside California 92506
Investigational Site Number 840035 Rolling Hills Estates California 90274
Investigational Site Number 840041 San Francisco California 94143
Investigational Site Number 840042 San Francisco California 94143
Investigational Site Number 840039 San Jose California 95117
Investigational Site Number 840024 Santa Rosa California 95405
Investigational Site Number 840002 Stockton California 95207
Investigational Site Number 840031 Colorado Springs Colorado 80907
Investigational Site Number 840011 Denver Colorado 80206
Investigational Site Number 840017 Denver Colorado 80230
Investigational Site Number 840026 New Haven Connecticut 06510
Investigational Site Number 840044 Tallahassee Florida 32308
Investigational Site Number 840029 Tampa Florida 33612
Investigational Site Number 840028 Indianapolis Indiana 46208
Investigational Site Number 840038 Iowa City Iowa 52240
Investigational Site Number 840021 Overland Park Kansas 66210
Investigational Site Number 840053 Owensboro Kentucky 42303
Investigational Site Number 840014 Baltimore Maryland 21287
Investigational Site Number 840015 North Dartmouth Massachusetts 02747
Investigational Site Number 840003 Minneapolis Minnesota 55402
Investigational Site Number 840010 Minneapolis Minnesota 55402
Investigational Site Number 840006 St Louis Missouri 63110
Investigational Site Number 840013 St Louis Missouri 63141
Investigational Site Number 840022 Bozeman Montana 59718
Investigational Site Number 840025 Omaha Nebraska 68131
Investigational Site Number 840008 Papillion Nebraska 27103
Investigational Site Number 840018 Princeton New Jersey 08540
Investigational Site Number 840004 Winston-Salem North Carolina 27157-1071
Investigational Site Number 840023 Sylvania Ohio 43560
Investigational Site Number 840045 Oklahoma City Oklahoma 73120
Investigational Site Number 840001 Lake Oswego Oregon 97035
Investigational Site Number 840012 Medford Oregon 97504
Investigational Site Number 840016 Portland Oregon 97209
Investigational Site Number 840040 Hershey Pennsylvania 17033
Investigational Site Number 840037 Pittsburgh Pennsylvania 15213
Investigational Site Number 840009 Upland Pennsylvania 19013
Investigational Site Number 840027 Charleston South Carolina 29407
Investigational Site Number 840030 El Paso Texas 79902
Investigational Site Number 840050 San Antonio Texas 78229
Investigational Site Number 840052 South Burlington Vermont 05403
Investigational Site Number 840049 Richmond Virginia 23229
Investigational Site Number 840020 Seattle Washington 98105
Investigational Site Number 840019 Tacoma Washington 98415-0299
Investigational Site Number 840034 Madison Wisconsin 53792

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01312961, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 7, 2017 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01312961 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →